Ability of serum to decrease cellular acylCoA: cholesterol acyl transferase activity predicts cardiovascular outcomes

Julio A. Chirinos, Juan P. Zambrano, Simon Chakko, Alan Schob, Ronald B Goldberg, Guido Perez, Armando J Mendez

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background - We evaluated whether cholesterol efflux activity of serum is associated with the presence of angiographic coronary artery disease (CAD) and the risk of major adverse cardiovascular events (MACE) and death. Methods and Results - We studied 168 men undergoing coronary angiography. Cholesterol efflux activity was measured in vitro by incubation of patient serum with human skin fibroblasts and defined as the ability of serum to decrease the pool of cholesterol available for esterification by the acylCoA:cholesterol acyl transferase (ACAT) reaction. We evaluated whether this activity was associated with the presence of CAD and the risk of MACE and death during a 4.5-year follow-up. Serum-induced changes in ACAT activity did not correlate with HDL levels or the presence of CAD. Patients in the highest tertile of change in ACAT activity had a significantly higher risk for MACE (HR, 2.15; 95% CI, 1.36 to 3.39; P=0.001) and death (HR, 2.23; 95% CI, 1.17 to 4.26; P=0.01). These correlations were independent of other risk markers including LDL, HDL, and C-reactive protein levels. Conclusions - Serum-induced depletion of cellular cholesterol available for esterification by ACAT was a strong, independent predictor of MACE and death. We speculate that the ability of serum to decrease ACAT activity depends on ATP binding cassette transporter A1 (ABCA1)-mediated efflux. Furthermore, serum samples that induce larger changes in ACAT activity contain increased levels of HDL particles that preferentially interact with ABCA1 and that these particles accumulate in the serum of patients because of low activity of ABCA1 in vivo preventing or limiting the extent of apoA-I lipidation.

Original languageEnglish
Pages (from-to)2446-2453
Number of pages8
JournalCirculation
Volume112
Issue number16
DOIs
StatePublished - Oct 18 2005

Fingerprint

Transferases
Cholesterol
Serum
ATP-Binding Cassette Transporters
Coronary Artery Disease
Esterification
Apolipoprotein A-I
Coronary Angiography
C-Reactive Protein
Fibroblasts
Skin

Keywords

  • Cardiovascular diseases
  • Cholesterol efflux
  • Lipoproteins
  • Morbidity
  • Risk factors

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Ability of serum to decrease cellular acylCoA : cholesterol acyl transferase activity predicts cardiovascular outcomes. / Chirinos, Julio A.; Zambrano, Juan P.; Chakko, Simon; Schob, Alan; Goldberg, Ronald B; Perez, Guido; Mendez, Armando J.

In: Circulation, Vol. 112, No. 16, 18.10.2005, p. 2446-2453.

Research output: Contribution to journalArticle

Chirinos, Julio A. ; Zambrano, Juan P. ; Chakko, Simon ; Schob, Alan ; Goldberg, Ronald B ; Perez, Guido ; Mendez, Armando J. / Ability of serum to decrease cellular acylCoA : cholesterol acyl transferase activity predicts cardiovascular outcomes. In: Circulation. 2005 ; Vol. 112, No. 16. pp. 2446-2453.
@article{03dd5d23e2cb4618ab37a5fa0eddd7a8,
title = "Ability of serum to decrease cellular acylCoA: cholesterol acyl transferase activity predicts cardiovascular outcomes",
abstract = "Background - We evaluated whether cholesterol efflux activity of serum is associated with the presence of angiographic coronary artery disease (CAD) and the risk of major adverse cardiovascular events (MACE) and death. Methods and Results - We studied 168 men undergoing coronary angiography. Cholesterol efflux activity was measured in vitro by incubation of patient serum with human skin fibroblasts and defined as the ability of serum to decrease the pool of cholesterol available for esterification by the acylCoA:cholesterol acyl transferase (ACAT) reaction. We evaluated whether this activity was associated with the presence of CAD and the risk of MACE and death during a 4.5-year follow-up. Serum-induced changes in ACAT activity did not correlate with HDL levels or the presence of CAD. Patients in the highest tertile of change in ACAT activity had a significantly higher risk for MACE (HR, 2.15; 95{\%} CI, 1.36 to 3.39; P=0.001) and death (HR, 2.23; 95{\%} CI, 1.17 to 4.26; P=0.01). These correlations were independent of other risk markers including LDL, HDL, and C-reactive protein levels. Conclusions - Serum-induced depletion of cellular cholesterol available for esterification by ACAT was a strong, independent predictor of MACE and death. We speculate that the ability of serum to decrease ACAT activity depends on ATP binding cassette transporter A1 (ABCA1)-mediated efflux. Furthermore, serum samples that induce larger changes in ACAT activity contain increased levels of HDL particles that preferentially interact with ABCA1 and that these particles accumulate in the serum of patients because of low activity of ABCA1 in vivo preventing or limiting the extent of apoA-I lipidation.",
keywords = "Cardiovascular diseases, Cholesterol efflux, Lipoproteins, Morbidity, Risk factors",
author = "Chirinos, {Julio A.} and Zambrano, {Juan P.} and Simon Chakko and Alan Schob and Goldberg, {Ronald B} and Guido Perez and Mendez, {Armando J}",
year = "2005",
month = "10",
day = "18",
doi = "10.1161/CIRCULATIONAHA.104.521815",
language = "English",
volume = "112",
pages = "2446--2453",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "16",

}

TY - JOUR

T1 - Ability of serum to decrease cellular acylCoA

T2 - cholesterol acyl transferase activity predicts cardiovascular outcomes

AU - Chirinos, Julio A.

AU - Zambrano, Juan P.

AU - Chakko, Simon

AU - Schob, Alan

AU - Goldberg, Ronald B

AU - Perez, Guido

AU - Mendez, Armando J

PY - 2005/10/18

Y1 - 2005/10/18

N2 - Background - We evaluated whether cholesterol efflux activity of serum is associated with the presence of angiographic coronary artery disease (CAD) and the risk of major adverse cardiovascular events (MACE) and death. Methods and Results - We studied 168 men undergoing coronary angiography. Cholesterol efflux activity was measured in vitro by incubation of patient serum with human skin fibroblasts and defined as the ability of serum to decrease the pool of cholesterol available for esterification by the acylCoA:cholesterol acyl transferase (ACAT) reaction. We evaluated whether this activity was associated with the presence of CAD and the risk of MACE and death during a 4.5-year follow-up. Serum-induced changes in ACAT activity did not correlate with HDL levels or the presence of CAD. Patients in the highest tertile of change in ACAT activity had a significantly higher risk for MACE (HR, 2.15; 95% CI, 1.36 to 3.39; P=0.001) and death (HR, 2.23; 95% CI, 1.17 to 4.26; P=0.01). These correlations were independent of other risk markers including LDL, HDL, and C-reactive protein levels. Conclusions - Serum-induced depletion of cellular cholesterol available for esterification by ACAT was a strong, independent predictor of MACE and death. We speculate that the ability of serum to decrease ACAT activity depends on ATP binding cassette transporter A1 (ABCA1)-mediated efflux. Furthermore, serum samples that induce larger changes in ACAT activity contain increased levels of HDL particles that preferentially interact with ABCA1 and that these particles accumulate in the serum of patients because of low activity of ABCA1 in vivo preventing or limiting the extent of apoA-I lipidation.

AB - Background - We evaluated whether cholesterol efflux activity of serum is associated with the presence of angiographic coronary artery disease (CAD) and the risk of major adverse cardiovascular events (MACE) and death. Methods and Results - We studied 168 men undergoing coronary angiography. Cholesterol efflux activity was measured in vitro by incubation of patient serum with human skin fibroblasts and defined as the ability of serum to decrease the pool of cholesterol available for esterification by the acylCoA:cholesterol acyl transferase (ACAT) reaction. We evaluated whether this activity was associated with the presence of CAD and the risk of MACE and death during a 4.5-year follow-up. Serum-induced changes in ACAT activity did not correlate with HDL levels or the presence of CAD. Patients in the highest tertile of change in ACAT activity had a significantly higher risk for MACE (HR, 2.15; 95% CI, 1.36 to 3.39; P=0.001) and death (HR, 2.23; 95% CI, 1.17 to 4.26; P=0.01). These correlations were independent of other risk markers including LDL, HDL, and C-reactive protein levels. Conclusions - Serum-induced depletion of cellular cholesterol available for esterification by ACAT was a strong, independent predictor of MACE and death. We speculate that the ability of serum to decrease ACAT activity depends on ATP binding cassette transporter A1 (ABCA1)-mediated efflux. Furthermore, serum samples that induce larger changes in ACAT activity contain increased levels of HDL particles that preferentially interact with ABCA1 and that these particles accumulate in the serum of patients because of low activity of ABCA1 in vivo preventing or limiting the extent of apoA-I lipidation.

KW - Cardiovascular diseases

KW - Cholesterol efflux

KW - Lipoproteins

KW - Morbidity

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=27144475030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144475030&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.104.521815

DO - 10.1161/CIRCULATIONAHA.104.521815

M3 - Article

C2 - 16230498

AN - SCOPUS:27144475030

VL - 112

SP - 2446

EP - 2453

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 16

ER -